Table 2.
Clinical Characteristics
| Study 1 | Study 2 | Study 3 | Study 4 | |||||
|---|---|---|---|---|---|---|---|---|
| Authors (year) | Pastori et al.( 5 ) | Goriacko et al.( 10 ) | Lee HF et al.( 11 ) | Lee SR et al.( 12 ) | ||||
| Study design | Prospective | Retrospective | Retrospective | Retrospective | ||||
| Anticoagulant | NOAC | VKA | NOAC | VKA | NOAC | VKA | NOAC | VKA |
| Follow‐up (months) | N/A | N/A | N/A | N/A | 13.56 | 15.6 | N/A | N/A |
| Sex (men, %) | 60.5 | 57.3 | 59.5 | 63.65 | 63.70 | 68.6 | 72.2 | |
| Mean CHA2DS2 VASc | 3.4 | N/A | N/A | 3.72 | 3.66 | 3.4 | 3.0 | |
| Mean age (years) | 78.9 | 66 | 65 | 72.81 | 72.41 | 69.5 | 66.9 | |
| NOACs/VKAs (n) | 52 | 77 | 75 | 158 | 1,438 (after PSSWs 1,397) | 990 (after PSSWs 946) | 446 | 322 |
| Dabigatran | N/A | 35 | 535 | 132 | ||||
| Apixaban | N/A | 11 | 171 | 94 | ||||
| Rivaroxaban | N/A | 29 | 732 | 190 | ||||
| Edoxaban | N/A | ‐* | ‐ | 30 | ||||
| Definition of LD | Advanced liver fibrosis (FIB‐4 >3.25) | Liver cirrhosis (Child‐Pugh A‐B‐C) | Liver cirrhosis (ICD‐9‐CM) | Liver cirrhosis (ICD‐10‐CM) | ||||
*‐ indicates none.
Abbreviations: CHA2DS2 VASc, congestive heart failure (1 point), hypertension (1 point), age (2 points if above 75), diabetes (1 point), previous stroke (2 points), vascular disease (1 point), age (1 point if between 65 and 74 years), sex (1 point if female); FIB‐4, fibrosis‐4; ICD‐9/10‐CM, International Classification of Diseases, Ninth/Tenth Revision, Clinical Modification; N/A, not applicable; NOAC, nonvitamin K anticoagulant; PSSW, propensity score‐based stabilized weight.